Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Kairos Pharma, Ltd

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Ltd. Provides Letter to Stockholders
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Provides Business Update and Outlook into 2025
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
From Kairos Pharma, Ltd
Via Business Wire
Tickers KAPA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.